Glenmark Pharmaceuticals has transferred its Active Pharmaceuticals Ingredient (API) business to Glenmark Life Sciences, a wholly owned subsidiary of the company. This transfer was completed on December 31, 2018.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).